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Cell-to-cellInhibitors targeting the hepatitis C virus (HCV) encoded viroporin, p7 prevent virus release in vitro. HCV
can transmit by cell-free particle infection of new target cells and via cell-to-cell dependent contact with
limited exposure to the extracellular environment. The role of assembly inhibitors in preventing HCV
transmission via these pathways has not been studied. We compared the efﬁcacy of three published
p7 inhibitors to inhibit cell-free and cell-to-cell transmission of two chimeric HCV strains encoding geno-
type 2 (GT2) or 5 (GT5) p7 using a recently developed single cycle co-culture assay. The inhibitors
reduced the infectivity of extracellular GT2 and GT5 virus by 80–90% and GT2 virus cell-to-cell transmis-
sion by 50%. However, all of the p7 inhibitors had minimal effect on GT5 cell contact dependent transmis-
sion. Screening a wider panel of diverse viral genotypes demonstrated that p7 viroporin inhibitors were
signiﬁcantly more effective at blocking cell-free virus than cell-to-cell transmission. These results suggest
an altered assembly or trafﬁcking of cell-to-cell transmitted compared to secreted virus. These observa-
tions have important implications for the validation, therapeutic design and testing of HCV assembly
inhibitors.
 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license.1. Results and discussion
Hepatitis C virus (HCV) is a global health problem, affecting
approximately 170million, and results in a chronic degenerative li-
ver disease that is characterised by hepatic ﬁbrosis, cirrhosis and in
10% of cases hepatocellular carcinoma. Therapeutic regimens of
pegylated-interferon and the nucleoside analogue ribavirin are
only active in about 50% of cases with varying efﬁcacy across dif-
ferent genotypes. More recently direct acting antivirals (DAAs) tar-
geting the viral encoded protease (telaprevir and boceprevir) and
polymerase (sofosbuvir) (Chang et al., 2012; Gane et al., 2013; Mat-
thews and Lancaster, 2012) have been developed and show in-
creased viral clearance rates. However, genotype-dependent
differences in drug sensitivity and viral resistance highlight the
need for additional drugs for future combination therapy.
The HCV encoded viroporin p7 is an attractive target for thera-
peutic intervention since it is essential for viral assembly and
egress (Tedbury et al., 2011; Wozniak et al., 2010). However, clin-ical trials of p7 inhibitors, including the adamantane-derivatives
amantadine and rimantadine, have showed limited efﬁcacy at con-
centrations that can be achieved in man, consistent with in vitro
observations (Fong et al., 1999; Grifﬁn et al., 2008; Jubin et al.,
2000; Steinmann et al., 2007a,b). A recent study by OuYang et al.,
elucidated an NMR structure of HCV p7 strain EUH1480 (GT5A)
and predicted the amantadine binding domain. Both amantadine
and rimantadine are suggested to hinder the p7 channel from
opening by restricting movement of helical segments in the p7
hexamer. The authors report variations in the adamantane-binding
pocket which may explain the broad range of responses to inhibi-
tors reported for diverse HCV genotypes (OuYang et al., 2013).
The majority of in vitro studies on p7 inhibitors have character-
ised the effect of compounds on virus assembly and the infectivity
of secreted particles. However, these studies did not address the
ability of HCV to transmit via cell-to-cell contacts, a dominant
route of viral transmission for several HCV genotypes (Brimacombe
et al., 2011; Catanese et al., 2013; Meredith et al., 2013; Timpe
et al., 2008). We therefore assessed the efﬁcacy of several known
p7 inhibitors to prevent HCV cell-to-cell transmission, including
the amantadine-derivative Rimantadine, the long alkyl-chain imi-
nosugar NN-DNJ (StGelais et al., 2007; Wozniak et al., 2010) and
the small molecule inhibitor BIT225 (Luscombe et al., 2010). We
previously reported that diverse strains of HCV can transmit effec-
tively via the cell-to-cell route, with J6/JFH (GT2A/2A) showing a
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Fig. 1. Differential effect of p7 inhibitors on hepatitis C virus cell-free and cell-to-cell transmission. (A) Schematic representation of co-culture assay. HCV strain J6/JFH (B) or
SA13/JFH (C) infectedHuh-7.5 cells or producerswere treated for 24 hwithp7 inhibitors,washed thoroughly, labelledwithCMFDAand co-cultured at a 1:1 ratiowithnaïveHuh-
7.5 target cells. Extracellular infectious virus was neutralised by the inclusion of anti-HCV IgG (150 lg/mL), parallel infections performed in the presence of a neutralising anti-
HCV Ig or control IgG allowedus to quantify the frequency of cell-free and cell-to-cell infection events. 2 h post contact of infected andnaïve cells a sample ofmediawas collected
tomeasure the effect of p7 inhibitors on extracellular infectious virus levels prior to the addition of neutralising anti-receptor CD81mAb (2s131) (10 lg/mL) to block all further
HCV infection events. Co-cultures were incubated for a further 20 h and the cells stained for viral encoded non-structural protein NS5A. Newly infected target cells (NS5A+/
CMFDA) were quantiﬁed per 105 producer cells by ﬂow cytometry. Results are the mean and standard deviation of three experiments and statistical signiﬁcance determined
using unpaired T-test with corrections for multiple comparisons (Signiﬁcance ⁄⁄⁄P < 0.001, ⁄⁄P < 0.01). (D) Additional viral genotypes were tested for their sensitivity to BIT225
(30 lM), Rimantadine (3 lM),NN-NDJ (30 lM)andNN-DGJ (30 lM), using the same assay protocol as described in (A). Signiﬁcant differenceswere observed between inhibition
of cell-to-cell and cell-free inhibition of infection for all drugs tested (⁄⁄BIT225, Rimantadine (P < 0.01), ⁄NN-DNJ, NN-DGJ (P < 0.05)).
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2A) transmitted with equal efﬁciency by either route (Brimacombe
et al., 2011; Meredith et al., 2013). Furthermore, HCV SA13/JFH is
the only published infectious GT5 strain and has a closely related
sequence to EUH1480, the subject of the recent p7 NMR study
(OuYang et al., 2013).
To determine the sensitivity of HCV J6/JFH and SA13/JFH to p7
inhibitors BIT225, NN-DNJ and rimantadine, infected Huh-7.5 cells
were treated overnight with increasing concentrations of com-
pound. The drug was removed by repeated washing, conditioned
media was collected over a 2 h period and infectivity measured.
All compounds were effective against both strains, although J6/
JFH was more sensitive than SA13/JFH, with IC90 values of 10, 3
and 0.3 lM for BIT225, NN-DNJ and Rimantadine, respectively,
compared to IC90 values of 30, 30 and 1 lM for SA13/JFH (data
not shown). The higher IC90 values reported here compared to pre-
vious studies most likely reﬂect differences in the duration of treat-
ment, with earlier studies treating infected cells for up to 72 h
before measuring extracellular virus infectivity. Since NN-DNJ
can affect glycosylation of viral proteins we limited the duration
of treatment to minimise such off-target effects.
The efﬁcacy of the inhibitors to limit HCV cell-to-cell transmis-
sion was tested using a recently developed single-cycle co-culture
assay (Meredith et al., 2013). Since p7 has been reported to play a
role in viral internalisation (Grifﬁn et al., 2008) it is important to
discriminate the effect of p7 inhibitors on virus assembly and en-
try. This assay allows one to assess the effect of p7 inhibitor treat-
ment on infected ‘producer’ cells and enables the quantiﬁcation of
new infection events within 2 h of culturing infected and naïve
hepatoma cells, which is essential given the reversible nature of
p7 targeted compounds (Pavlovic et al., 2005, 2003). HCV J6/JFH
or SA13/JFH infected Huh-7.5 cells were treated with 30 lM of
either BIT225 or NN-DNJ and 3 lM Rimantadine for 24 h, concen-
trations previously shown to inhibit the level of infectious extra-
cellular virus by 80–90%. The cells were washed to remove the
compounds, labelled with 5-Chloromethylﬂuorescein diacetate
(CMFDA Cell Tracker Green, Invitrogen), and cultured with naïve
Huh-7.5 targets at a 1:1 ratio as detailed in Fig. 1A. We conﬁrmed
that all compounds reduced the level of extracellular infectious
virus in the co-culture (Fig. 1B and C), consistent with a reduction
in J6/JFH and SA13/JFH cell-free transmission events. Although all
three compounds inhibited 50–70% of J6/JFH cell-to-cell transmis-
sion, they had no detectable effect on SA13/JFH cell-to-cell trans-
mission (Fig. 1C). To determine how wide ranging this effect was,
we screened a panel of diverse chimeric viruses expressing the
structural proteins from genotype 1–7 for their sensitivity to all
currently available p7 inhibitors, including NN-DGJ that does not
affect host cell glycosylation pathways (Chapel et al., 2006a,b,c).
Three viruses (JFH-1 – GT2; ED43/JFH – GT3 and QC69/JFH –
GT7) showed limited transmission and were excluded from the
analysis. The results show that all of the p7 inhibitors were signif-
icantly more effective at inhibiting cell-free infection than cell-to-
cell transmission when all genotypes are considered (Fig. 1D).
The recent study by OuYang et al., suggest that amantadine
binds the p7 ion-channel and locks it into a closed position (OuY-
ang et al., 2013), preventing the de-acidiﬁcation of the intravesic-
ular compartments and leading to the secretion of non-infectious
virus. Our study suggests that virus transmitting via cell-to-cell
contact may have differential sensitivity to low pH compared to
the secreted virus. Further experiments are needed to investigate
the role of vesicular pH in HCV cell-to-cell transmission, as these
results may indicate that p7 activity may be dispensable for this
mode of infection. However the studies presented here focus on
existing compounds that speciﬁcally target the function of p7 as
a viroporin, and do not take into account roles that p7 may play
in mediating capsid assembly and envelopment (Gentzsch et al.,2013), HCV assembly complex formation (Shanmugam and Yi,
2013) or other aspects of the viral life cycle. This study has impor-
tant implications for the therapeutic design and evaluation of
agents targeting HCV p7, or other assembly inhibitors, that may in-
hibit the secretion of virus detected in the periphery but have min-
imal effect on viral spread within the liver, limiting their
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